Trial Profile
A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere-Containing Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Mitoxantrone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TROPIC
- Sponsors Sanofi
- 29 Jan 2016 Results (post-hoc analysis) published in the European Journal of Cancer.
- 08 May 2013 Final quality-of-life and tolerability results presented at the 108th Annual Meeting of the American Urological Association.
- 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.